Metformin prevents periodontal disease (PD) in non-diabetics.
This was a small randomized controlled trial in humans. The paper also includes a mouse study that showed similar results to the human study.
Quoted:
“Conclusion—
This is the first study to demonstrate that systemic interventions using Metformin in non-diabetic individuals aimed at PD prevention have oral-systemic effects constituting a possible novel form of preventive medicine for oral-systemic disease management.”
Note:
Periodontal disease is known to be driven by the aging process itself. That’s why it is much more common in older people. Interventions that slow aging in animal models, e.g. calorie restriction, also lower the chances of the animals developing PD.
Given that rapamycin has also been shown to prevent/reverse periodontal disease in animal models by different mechanisms, it seems likely that the effects of rapamycin+metformin would be additive or synergistic in PD. This may be an example of how these two drugs might work together to slow certain aspects of the aging process.
Paper · J Transl Med · 2023Repurposing Metformin for periodontal disease management as a form of oral-systemic preventive medicineBackground Despite the improvements in treatment over the last decades, periodontal disease (PD) affects millions of people around the world and the only treatment available is based on controlling microbial load. Diabetes is known to increase the risk of PD establishment and progression, and recently, glucose metabolism modulation by pharmaceutical or dietarian means has been emphasised as a significant modulator…translational-medicine.biomedcentral.com

